Orgenesis Inc
Buy, Hold or Sell?
Let's analyze Orgenesis together
I guess you are interested in Orgenesis Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of Orgenesis Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
Get notifications about Orgenesis Inc
I send you an email if I find something interesting about Orgenesis Inc.
1. Quick Overview
1.1. Quick analysis of Orgenesis (30 sec.)
1.2. What can you expect buying and holding a share of Orgenesis? (30 sec.)
How much money do you get?
What is your share worth?
+ What do you gain per year?
2. Detailed Analysis
2.1. Valuation of Orgenesis (5 min.)
2.2. Growth of Orgenesis (5 min.)
Is Orgenesis growing?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
How rich? | -$15.7m | $43.1m | -$56.1m | -432.8% |
How much money is Orgenesis making?
Current year | Previous year | Grow | Grow % | |
---|---|---|---|---|
Making money | -$10.1m | -$2.7m | -$7.3m | -72.6% |
Net Profit Margin | 302.6% | -36.7% | - | - |
How much money comes from the company's main activities?
2.3. Financial Health of Orgenesis (5 min.)
2.4. Comparing to competitors in the Biotechnology industry (5 min.)
Industry Rankings (Biotechnology)
3. Summary and Key Metrics
3.1. What can you expect buying and holding a share of Orgenesis?
Welcome investor! Orgenesis's management wants to use your money to grow the business. In return you get a share of Orgenesis.
First you should know what it really means to hold a share of Orgenesis. And how you can make/lose money.
Speculation
The Price per Share of Orgenesis is $1.18. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.
If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:
- The fundamentals: the financial health trends of Orgenesis.
- The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
- The book value: what is the market price compared to it's book value.
Investing
If you really want to invest in Orgenesis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:
- You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.41. Based on the TTM, the Book Value Change Per Share is $-0.31 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.11 per quarter.
- You may receive quarterly/yearly dividend in the form of additional shares.
- You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
How much money are you going to get?
MRQ | TTM | YOY | 5Y | 10Y | ||||||
---|---|---|---|---|---|---|---|---|---|---|
$ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | |
Usd Eps | -0.23 | -19.4% | -0.29 | -24.9% | -0.13 | -11.1% | -0.11 | -9.2% | -0.24 | -19.9% |
Usd Book Value Change Per Share | 0.42 | 35.9% | -0.31 | -26.5% | -0.11 | -9.3% | -0.09 | -7.2% | 0.00 | -0.2% |
Usd Dividend Per Share | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.1% | 0.00 | 0.2% | 0.00 | 0.1% |
Usd Total Gains Per Share | 0.42 | 35.9% | -0.31 | -26.5% | -0.11 | -9.2% | -0.08 | -7.0% | 0.00 | -0.1% |
Usd Price Per Share | 0.60 | - | 0.64 | - | 1.49 | - | 2.86 | - | 2.69 | - |
Price to Earnings Ratio | -0.65 | - | -0.28 | - | -3.47 | - | -9.10 | - | -5.02 | - |
Price-to-Total Gains Ratio | 1.42 | - | -1.36 | - | -8.53 | - | -9.14 | - | -2.28 | - |
Price to Book Ratio | -1.48 | - | -0.44 | - | 1.05 | - | 2.12 | - | 1.71 | - |
Price-to-Total Gains Ratio | 1.42 | - | -1.36 | - | -8.53 | - | -9.14 | - | -2.28 | - |
When do you get the money?
Usd Investment | |
---|---|
Usd Price Per Share | 1.18 |
Number of shares | 847 |
Gains per Quarter | Trailing 12 Months | 5 Year |
---|---|---|
Usd Dividend Per Share | 0.00 | 0.00 |
Usd Book Value Change Per Share | -0.31 | -0.09 |
Usd Total Gains Per Share | -0.31 | -0.08 |
Gains per Quarter (847 shares) | -265.00 | -70.21 |
Gains per Year (847 shares) | -1,059.99 | -280.86 |
Years | Return on Investment (TTM) | Return on Investment (5Y) | ||||
---|---|---|---|---|---|---|
Dividend | Book Value gain | Total gains | Dividend | Book Value gain | Total gains | |
Broker costs | - | - | -10 | - | - | -10 |
1 | 0 | -1060 | -1070 | 9 | -290 | -291 |
2 | 0 | -2120 | -2130 | 18 | -579 | -572 |
3 | 0 | -3180 | -3190 | 26 | -869 | -853 |
4 | 0 | -4240 | -4250 | 35 | -1159 | -1134 |
5 | 0 | -5300 | -5310 | 44 | -1448 | -1415 |
6 | 0 | -6360 | -6370 | 53 | -1738 | -1696 |
7 | 0 | -7420 | -7430 | 62 | -2028 | -1977 |
8 | 0 | -8480 | -8490 | 70 | -2317 | -2258 |
9 | 0 | -9540 | -9550 | 79 | -2607 | -2539 |
10 | 0 | -10600 | -10610 | 88 | -2897 | -2820 |
How sure are you?
Based on the past periods, how sure are you to get value out of your investment.
Linear %
Trailing 12 Months | 3Y | 5 Year | 10 Year | ALLTIME | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | % | % | % | % | ||||||||||||||||
Earnings Per Share | 1.0 | 3.0 | 0.0 | 25.0% | 1.0 | 10.0 | 0.0 | 9.1% | 2.0 | 15.0 | 0.0 | 11.8% | 6.0 | 31.0 | 0.0 | 16.2% | 6.0 | 49.0 | 0.0 | 10.9% |
Book Value Change Per Share | 1.0 | 3.0 | 0.0 | 25.0% | 2.0 | 9.0 | 0.0 | 18.2% | 3.0 | 14.0 | 0.0 | 17.6% | 12.0 | 25.0 | 0.0 | 32.4% | 18.0 | 37.0 | 0.0 | 32.7% |
Dividend per Share | 0.0 | 0.0 | 4.0 | 0.0% | 2.0 | 0.0 | 9.0 | 18.2% | 2.0 | 0.0 | 15.0 | 11.8% | 2.0 | 0.0 | 35.0 | 5.4% | 2.0 | 0.0 | 53.0 | 3.6% |
Total Gains per Share | 1.0 | 3.0 | 0.0 | 25.0% | 2.0 | 9.0 | 0.0 | 18.2% | 3.0 | 14.0 | 0.0 | 17.6% | 12.0 | 25.0 | 0.0 | 32.4% | 18.0 | 37.0 | 0.0 | 32.7% |
3.2. Key Performance Indicators
The key performance indicators of Orgenesis Inc compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | 0.424 | -0.313 | +174% | -0.109 | +126% | -0.085 | +120% | -0.002 | +100% |
Book Value Per Share | - | - | -0.406 | -0.369 | -9% | 1.654 | -125% | 1.375 | -130% | 1.048 | -139% |
Current Ratio | - | - | 0.074 | 0.251 | -70% | 2.031 | -96% | 2.082 | -96% | 1.293 | -94% |
Debt To Asset Ratio | - | - | 1.516 | 1.644 | -8% | 0.462 | +228% | 0.736 | +106% | 0.941 | +61% |
Debt To Equity Ratio | - | - | - | 0.664 | -100% | 1.250 | -100% | 1.975 | -100% | 1.738 | -100% |
Dividend Per Share | - | - | - | - | 0% | 0.001 | -100% | 0.003 | -100% | 0.001 | -100% |
Eps | - | - | -0.229 | -0.294 | +28% | -0.131 | -43% | -0.109 | -52% | -0.235 | +3% |
Free Cash Flow Per Share | - | - | -0.152 | -0.090 | -41% | -0.371 | +144% | -0.427 | +181% | -0.307 | +102% |
Free Cash Flow To Equity Per Share | - | - | 0.016 | -0.040 | +361% | -0.186 | +1300% | -0.319 | +2153% | -0.101 | +752% |
Gross Profit Margin | - | - | 1.025 | 1.087 | -6% | 2.101 | -51% | 1.289 | -20% | 1.133 | -10% |
Intrinsic Value_10Y_max | - | - | 90.096 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -9.849 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | 0.391 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -1.195 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | 7.756 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -3.433 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | 23.059 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -5.478 | - | - | - | - | - | - | - | - |
Market Cap | 5629520.400 | -314% | 23316436.200 | 21130808.402 | +10% | 39069113.330 | -40% | 65327987.713 | -64% | 47147891.827 | -51% |
Net Profit Margin | - | - | -36.195 | 3.026 | -1296% | -0.367 | -99% | -1.705 | -95% | -1.391 | -96% |
Operating Margin | - | - | -16.537 | -23.834 | +44% | -0.178 | -99% | -8.391 | -49% | -4.589 | -72% |
Operating Ratio | - | - | 17.537 | 24.763 | -29% | 1.222 | +1335% | 9.276 | +89% | 5.385 | +226% |
Pb Ratio | -2.904 | -97% | -1.476 | -0.441 | -70% | 1.050 | -241% | 2.120 | -170% | 1.715 | -186% |
Pe Ratio | -1.288 | -97% | -0.655 | -0.278 | -58% | -3.468 | +430% | -9.102 | +1290% | -5.020 | +667% |
Price Per Share | 1.180 | +49% | 0.600 | 0.636 | -6% | 1.485 | -60% | 2.856 | -79% | 2.688 | -78% |
Price To Free Cash Flow Ratio | -1.940 | -97% | -0.987 | -3.156 | +220% | -1.100 | +12% | -2.279 | +131% | -2.334 | +137% |
Price To Total Gains Ratio | 2.783 | +49% | 1.415 | -1.356 | +196% | -8.528 | +703% | -9.141 | +746% | -2.276 | +261% |
Quick Ratio | - | - | 0.044 | 0.210 | -79% | 1.952 | -98% | 1.987 | -98% | 1.183 | -96% |
Return On Assets | - | - | -0.291 | -0.673 | +131% | -0.039 | -87% | -0.246 | -15% | -0.214 | -27% |
Return On Equity | - | - | - | 0.255 | -100% | -0.105 | 0% | -0.163 | 0% | -0.184 | 0% |
Total Gains Per Share | - | - | 0.424 | -0.313 | +174% | -0.109 | +126% | -0.083 | +120% | -0.001 | +100% |
Usd Book Value | - | - | -15792000.000 | -12981750.000 | -18% | 43199250.000 | -137% | 31247352.941 | -151% | 20073319.865 | -179% |
Usd Book Value Change Per Share | - | - | 0.424 | -0.313 | +174% | -0.109 | +126% | -0.085 | +120% | -0.002 | +100% |
Usd Book Value Per Share | - | - | -0.406 | -0.369 | -9% | 1.654 | -125% | 1.375 | -130% | 1.048 | -139% |
Usd Dividend Per Share | - | - | - | - | 0% | 0.001 | -100% | 0.003 | -100% | 0.001 | -100% |
Usd Eps | - | - | -0.229 | -0.294 | +28% | -0.131 | -43% | -0.109 | -52% | -0.235 | +3% |
Usd Free Cash Flow | - | - | -5908000.000 | -3147750.000 | -47% | -9683000.000 | +64% | -10023529.412 | +70% | -5860133.243 | -1% |
Usd Free Cash Flow Per Share | - | - | -0.152 | -0.090 | -41% | -0.371 | +144% | -0.427 | +181% | -0.307 | +102% |
Usd Free Cash Flow To Equity Per Share | - | - | 0.016 | -0.040 | +361% | -0.186 | +1300% | -0.319 | +2153% | -0.101 | +752% |
Usd Market Cap | 5629520.400 | -314% | 23316436.200 | 21130808.402 | +10% | 39069113.330 | -40% | 65327987.713 | -64% | 47147891.827 | -51% |
Usd Price Per Share | 1.180 | +49% | 0.600 | 0.636 | -6% | 1.485 | -60% | 2.856 | -79% | 2.688 | -78% |
Usd Profit | - | - | -8904000.000 | -10102000.000 | +13% | -2767000.000 | -69% | -9403294.118 | +6% | -5964291.378 | -33% |
Usd Revenue | - | - | 246000.000 | -3275500.000 | +1432% | 8907750.000 | -97% | 4695000.000 | -95% | 3594270.270 | -93% |
Usd Total Gains Per Share | - | - | 0.424 | -0.313 | +174% | -0.109 | +126% | -0.083 | +120% | -0.001 | +100% |
EOD | +5 -3 | MRQ | TTM | +21 -13 | YOY | +13 -22 | 5Y | +14 -21 | 10Y | +14 -21 |
3.3 Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | -1.288 | |
Price to Book Ratio (EOD) | Between | 0-1 | -2.904 | |
Net Profit Margin (MRQ) | Greater than | 0 | -36.195 | |
Operating Margin (MRQ) | Greater than | 0 | -16.537 | |
Quick Ratio (MRQ) | Greater than | 1 | 0.044 | |
Current Ratio (MRQ) | Greater than | 1 | 0.074 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 1.516 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 0.000 | |
Return on Equity (MRQ) | Greater than | 0.15 | 0.000 | |
Return on Assets (MRQ) | Greater than | 0.05 | -0.291 | |
Total | 1/10 (10.0%) |
3.4 Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 26.037 | |
Ma 20 | Greater than | Ma 50 | 1.788 | |
Ma 50 | Greater than | Ma 100 | 3.846 | |
Ma 100 | Greater than | Ma 200 | 5.415 | |
Open | Greater than | Close | 1.180 | |
Total | 0/5 (0.0%) |
4. In-depth Analysis
4.1 About Orgenesis Inc
- https://orgenesis.com
- Biotechnology
- 146
- 20271 Goldenrod Lane, Germantown, MD, United States, 20876
Google Maps Bing Maps
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
Fundamental data was last updated by Penke on 2024-10-24 22:42:04.
4.2 In-depth Summary
4.2.1. Financial Health Summary
Compared to previous year | Compared to industry | |
---|---|---|
The company is making a huge profit. | ||
Using its assets, the company is very inefficient in making profit. | ||
Using its investors money, the company is very efficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is operating very inefficient. | ||
The company is inefficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is unable to pay all its short-term debts. | ||
The company is just not able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is unable to pay all its debts by selling its assets. | ||
The company is very able to pay all its debts with equity. |
4.2.2. Valuation Summary
Compared to previous year | Compared to industry | |
---|---|---|
Based on the equity, the company is expensive. | ||
Based on the earnings, the company is expensive. | ||
Based on how much money comes from the company's main activities, the company is expensive. |
4.3 Financial Health
4.3.1. Profitability
4.3.1 Profitability
4.3.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
- A Net Profit Margin of -3,619.5% means that $-36.20 for each $1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of Orgenesis Inc:
Trends
- The YOY is -36.7%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is -170.5%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is -139.1%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -3,619.5% | TTM | 302.6% | -3,922.2% | |
TTM | 302.6% | YOY | -36.7% | +339.3% | |
TTM | 302.6% | 5Y | -170.5% | +473.2% | |
5Y | -170.5% | 10Y | -139.1% | -31.4% |
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -135.3%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -204.4%. trending up. +2
4.3.1.2. Return on Assets
- Above 5% is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
- -29.1% Return on Assets means that Orgenesis generated $-0.29 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of Orgenesis Inc:
Trends
- The YOY is -3.9%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -24.6%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -21.4%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -29.1% | TTM | -67.3% | +38.2% | |
TTM | -67.3% | YOY | -3.9% | -63.4% | |
TTM | -67.3% | 5Y | -24.6% | -42.6% | |
5Y | -24.6% | 10Y | -21.4% | -3.3% |
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -10.7%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -11.8%. trending down. -2
4.3.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
- 0.0% Return on Equity means Orgenesis generated $0.00 for each $1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of Orgenesis Inc:
- The MRQ is 0.0%. The data is not here.
Trends
- The YOY is -10.5%. Compared to the TTM, the mid term is trending up. +2
- The 5Y is -16.3%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is -18.4%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | - | TTM | 25.5% | -25.5% | |
TTM | 25.5% | YOY | -10.5% | +36.0% | |
TTM | 25.5% | 5Y | -16.3% | +41.8% | |
5Y | -16.3% | 10Y | -18.4% | +2.1% |
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -13.5%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -15.9%. trending up. +2
4.3.2. Operating Efficiency of Orgenesis Inc.
4.3.2. Operating Efficiency
4.3.2.1. Operating Margin
- Measures how much profit Orgenesis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
- An Operating Margin of -1,653.7% means the company generated $-16.54 for each $1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of Orgenesis Inc:
Trends
- The YOY is -17.8%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -839.1%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is -458.9%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -1,653.7% | TTM | -2,383.4% | +729.8% | |
TTM | -2,383.4% | YOY | -17.8% | -2,365.7% | |
TTM | -2,383.4% | 5Y | -839.1% | -1,544.3% | |
5Y | -839.1% | 10Y | -458.9% | -380.2% |
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -277.1%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -312.4%. trending down. -2
4.3.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Biotechnology industry mean).
- An Operation Ratio of 17.54 means that the operating costs are $17.54 for each $1 in net sales.
Let's take a look of the Operating Ratio trends of Orgenesis Inc:
Trends
- The YOY is 1.222. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 9.276. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 5.385. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 17.537 | TTM | 24.763 | -7.226 | |
TTM | 24.763 | YOY | 1.222 | +23.541 | |
TTM | 24.763 | 5Y | 9.276 | +15.487 | |
5Y | 9.276 | 10Y | 5.385 | +3.890 |
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.842. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 3.179. trending up. -2
4.4.3. Liquidity of Orgenesis Inc.
4.4.3. Liquidity
4.4.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
- A Current Ratio of 0.07 means the company has $0.07 in assets for each $1 in short-term debts.
Let's take a look of the Current Ratio trends of Orgenesis Inc:
Trends
- The YOY is 2.031. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 2.082. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 1.293. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.074 | TTM | 0.251 | -0.177 | |
TTM | 0.251 | YOY | 2.031 | -1.780 | |
TTM | 0.251 | 5Y | 2.082 | -1.832 | |
5Y | 2.082 | 10Y | 1.293 | +0.789 |
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.783. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 3.923. trending down. -2
4.4.3.2. Quick Ratio
- Above 1 is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
- A Quick Ratio of 0.04 means the company can pay off $0.04 for each $1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of Orgenesis Inc:
Trends
- The YOY is 1.952. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 1.987. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 1.183. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.044 | TTM | 0.210 | -0.166 | |
TTM | 0.210 | YOY | 1.952 | -1.742 | |
TTM | 0.210 | 5Y | 1.987 | -1.777 | |
5Y | 1.987 | 10Y | 1.183 | +0.803 |
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.349. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 3.522. trending down. -2
4.5.4. Solvency of Orgenesis Inc.
4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare Orgenesis to Biotechnology industry mean.
- A Debt to Asset Ratio of 1.52 means that Orgenesis assets are financed with 151.6% credit (debt) and the remaining percentage (100% - 151.6%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of Orgenesis Inc:
Trends
- The YOY is 0.462. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.736. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.941. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 1.516 | TTM | 1.644 | -0.127 | |
TTM | 1.644 | YOY | 0.462 | +1.182 | |
TTM | 1.644 | 5Y | 0.736 | +0.908 | |
5Y | 0.736 | 10Y | 0.941 | -0.205 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.338. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 0.347. trending up. -2
4.5.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
- A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of Orgenesis Inc:
- The MRQ is 0.000. The data is not here.
Trends
- The YOY is 1.250. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 1.975. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 1.738. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | - | TTM | 0.664 | -0.664 | |
TTM | 0.664 | YOY | 1.250 | -0.586 | |
TTM | 0.664 | 5Y | 1.975 | -1.312 | |
5Y | 1.975 | 10Y | 1.738 | +0.237 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.389. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.437. trending up. -2
4.6. Market Valuation
4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare Orgenesis to the Biotechnology industry mean.
- A PE ratio of -0.65 means the investor is paying $-0.65 for every $1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of Orgenesis Inc:
Trends
- The YOY is -3.468. Compared to the TTM, the mid term is trending up. -2
- The 5Y is -9.102. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is -5.020. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -1.288 | MRQ | -0.655 | -0.633 | |
MRQ | -0.655 | TTM | -0.278 | -0.377 | |
TTM | -0.278 | YOY | -3.468 | +3.191 | |
TTM | -0.278 | 5Y | -9.102 | +8.824 | |
5Y | -9.102 | 10Y | -5.020 | -4.082 |
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -2.454. trending up. -2
- The TTM average (mean) in the Biotechnology industry is -2.994. trending up. -2
4.6.2.2. Price To Free Cash Flow Ratio
Let's take a look of the Price To Free Cash Flow Ratio trends of Orgenesis Inc:
- The EOD is -1.940. Based on how much money comes from the company's main activities, the company is expensive. -2
- The MRQ is -0.987. Based on how much money comes from the company's main activities, the company is expensive. -2
- The TTM is -3.156. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
- The YOY is -1.100. Compared to the TTM, the mid term is trending down. +2
- The 5Y is -2.279. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is -2.334. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -1.940 | MRQ | -0.987 | -0.954 | |
MRQ | -0.987 | TTM | -3.156 | +2.169 | |
TTM | -3.156 | YOY | -1.100 | -2.055 | |
TTM | -3.156 | 5Y | -2.279 | -0.877 | |
5Y | -2.279 | 10Y | -2.334 | +0.055 |
Compared to industry (Biotechnology)
Let compare the company's priceToFreeCashFlowRatio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -3.234. trending up. -2
- The TTM average (mean) in the Biotechnology industry is -3.528. trending up. -2
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Biotechnology industry mean).
- A PB ratio of -1.48 means the investor is paying $-1.48 for each $1 in book value.
Let's take a look of the Price to Book Ratio trends of Orgenesis Inc:
Trends
- The YOY is 1.050. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 2.120. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 1.715. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -2.904 | MRQ | -1.476 | -1.427 | |
MRQ | -1.476 | TTM | -0.441 | -1.036 | |
TTM | -0.441 | YOY | 1.050 | -1.491 | |
TTM | -0.441 | 5Y | 2.120 | -2.561 | |
5Y | 2.120 | 10Y | 1.715 | +0.406 |
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 1.983. trending down. -2
- The TTM average (mean) in the Biotechnology industry is 2.193. trending down. -2
4.6.2. Total Gains per Share
4.7 Holders & Insider Transactions
Let's take a look at which institutions, funds and insiders are holding shares of Orgenesis Inc.
4.8.1. Institutions holding Orgenesis Inc
Institutions are holding 4.546% of the shares of Orgenesis Inc.
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2024-06-30 | Vanguard Group Inc | 1.908 | 0 | 910250 | -14863 | -1.6066 |
2024-06-30 | Geode Capital Management, LLC | 0.5934 | 0 | 283077 | -4878 | -1.694 |
2024-06-30 | BlackRock Inc | 0.1675 | 0 | 79889 | -45336 | -36.2036 |
2024-06-30 | State Street Corp | 0.1653 | 0 | 78878 | 11219 | 16.5817 |
2024-06-30 | Northern Trust Corp | 0.0849 | 0 | 40512 | -161 | -0.3958 |
2024-06-30 | Bank Hapoalim BM | 0.0672 | 0.0027 | 32052 | 0 | 0 |
2024-06-30 | Renaissance Technologies Corp | 0.0618 | 0 | 29499 | -5100 | -14.7403 |
2024-06-30 | CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 0.0384 | 0 | 18330 | 0 | 0 |
2024-06-30 | XTX Topco Ltd | 0.0341 | 0.0008 | 16280 | 16280 | 0 |
2024-06-30 | Virtu Financial LLC | 0.0254 | 0.0005 | 12112 | 12112 | 0 |
2024-06-30 | UBS Group AG | 0.0131 | 0 | 6273 | 6273 | 0 |
2024-06-30 | Tower Research Capital LLC | 0.0013 | 0 | 631 | 631 | 0 |
2024-06-30 | Royal Bank of Canada | 0.001 | 0 | 465 | 361 | 347.1154 |
2024-06-30 | Bank of America Corp | 0.001 | 0 | 464 | 264 | 132 |
2024-06-30 | JPMorgan Chase & Co | 0.0003 | 0 | 159 | 4 | 2.5806 |
2024-06-30 | BNP Paribas Arbitrage, SA | 0.0002 | 0 | 75 | 0 | 0 |
2024-06-30 | Qube Research & Technologies | 0 | 0 | 2 | 0 | 0 |
2024-06-30 | Wells Fargo & Co | 0 | 0 | 0 | -242 | -100 |
2024-06-30 | Jane Street Group LLC | 0 | 0 | 0 | -11998 | -100 |
2024-03-31 | Prudential Financial Inc | 0 | 0 | 0 | -11000 | -100 |
Total | 3.1629 | 0.004 | 1508948 | -46434 | -3.1% |
4.9.2. Funds holding Orgenesis Inc
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2024-08-31 | Vanguard Total Stock Mkt Idx Inv | 1.1878 | 0 | 566688 | 0 | 0 |
2024-08-31 | Vanguard Institutional Extnd Mkt Idx Tr | 0.6308 | 0.0002 | 300957 | 0 | 0 |
2024-08-31 | Fidelity Extended Market Index | 0.3685 | 0.0003 | 175822 | -2829 | -1.5835 |
2024-08-31 | Fidelity Total Market Index | 0.0856 | 0 | 40821 | 0 | 0 |
2024-08-31 | Vanguard Balanced Index Inv | 0.0676 | 0 | 32261 | 0 | 0 |
2024-08-31 | Fidelity Series Total Market Index | 0.0596 | 0 | 28411 | 0 | 0 |
2023-12-31 | SSgA U.S. Extended Market Index Class I | 0.044 | 0.0004 | 21000 | 0 | 0 |
2024-06-30 | Northern Trust Extended Eq Market Idx | 0.043 | 0.0002 | 20527 | 0 | 0 |
2024-08-31 | Spartan Total Market Index Pool E | 0.0332 | 0 | 15827 | 6329 | 66.6351 |
2024-08-31 | Fidelity Nasdaq Composite Index | 0.0313 | 0.0001 | 14931 | 0 | 0 |
2024-03-31 | Vanguard Instl Ttl Stck Mkt Idx Tr | 0.0312 | 0 | 14863 | 0 | 0 |
2024-08-31 | Spartan Extended Market Index Pool E | 0.0282 | 0.0002 | 13471 | 2829 | 26.5833 |
2024-09-30 | BlackRock Extended Equity Market K | 0.1089 | 0.0002 | 5195 | -3 | -0.0577 |
2024-09-30 | NT Ext Equity Mkt Idx Fd - L | 0.043 | 0.0001 | 2053 | 0 | 0 |
2024-06-30 | Northern Trust Wilshire 5000 | 0.0041 | 0 | 1968 | 0 | 0 |
2024-09-30 | NT Ext Equity Mkt Idx Fd - NL | 0.0378 | 0.0001 | 1802 | 0 | 0 |
2024-09-30 | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 0.0304 | 0.0001 | 1452 | 4 | 0.2762 |
2024-09-30 | Vanguard U.S. Eq Idx £ Acc | 0.0217 | 0 | 1034 | 0 | 0 |
2024-09-30 | Extended Equity Market Fund M | 0.0138 | 0.0002 | 659 | -2 | -0.3026 |
2023-12-31 | NT US Market Cap Idx Fd - L | 0.0009 | 0 | 417 | -2105 | -83.4655 |
Total | 2.8714 | 0.0021 | 1260159 | +4223 | +0.3% |
5.3. Insider Transactions
Insiders are holding 21.166% of the shares of Orgenesis Inc.
5. Financial Statements
5.1. Latest Balance Sheet
Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 46,369 |
Total Stockholder Equity | + -15,498 |
Total Assets | = 30,577 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 17,706 |
Goodwill | 1,211 |
Long Term Investments | 8 |
Intangible Assets | 8,724 |
Long-term Assets Other | 331 |
Long-term Assets (as reported) | 28,229 |
---|---|
Long-term Assets (calculated) | 27,980 |
+/- | 249 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Other
5.2. Balance Sheets Structured
Currency in USD. All numbers in thousands.
Trend | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-05-31 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-11-30 | 2009-09-30 | 2009-03-31 | 2008-12-31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 30,577 | 30,920 | 14,552 | 45,299 | 54,767 | 93,267 | 90,928 | 70,690 | 62,799 | 58,538 | 59,841 | 65,204 | 75,558 | 82,110 | 77,684 | 110,752 | 119,196 | 127,209 | 92,495 | 79,599 | 84,555 | 84,770 | 75,447 | 69,296 | 47,033 | 42,411 | 39,872 | 37,422 | 36,267 | 36,272 | 33,487 | 36,555 | 36,746 | 36,200 | 38,748 | 35,551 | 34,584 | 1,227 | 2,249 | 1,660 | 154 | 293 | 600 | 114 | 1,133 | 98 | 48 | 350 | 182 | 354 | 2 | 5 | 6 | 7 | 2 | 20 | 23 | 27 | 32 | 32 | 34 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Total Current Assets |
| 2,348 | 1,956 | 4,076 | 8,776 | 9,295 | 49,450 | 46,318 | 31,856 | 25,458 | 24,010 | 25,758 | 36,341 | 47,848 | 54,713 | 50,077 | 94,983 | 104,312 | 112,930 | 25,979 | 20,773 | 27,092 | 23,932 | 30,297 | 24,654 | 13,738 | 8,569 | 7,295 | 5,674 | 6,110 | 7,428 | 4,205 | 5,292 | 5,147 | 5,055 | 8,206 | 2,999 | 2,511 | 1,202 | 2,230 | 1,640 | 135 | 277 | 583 | 98 | 1,118 | 83 | 39 | 340 | 175 | 354 | 2 | 5 | 6 | 7 | 2 | 5 | 8 | 12 | 17 | 17 | 19 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash And Cash Equivalents |
| 1,156 | 565 | 837 | 55 | 180 | 2,674 | 5,311 | 3,015 | 2,303 | 1,123 | 5,473 | 14,917 | 28,431 | 41,841 | 44,923 | 88,758 | 97,487 | 107,069 | 11,388 | 10,054 | 16,111 | 14,361 | 16,064 | 16,741 | 4,502 | 4,225 | 3,519 | 762 | 658 | 3,872 | 891 | 270 | 474 | 933 | 4,168 | 264 | 185 | 520 | 1,314 | 1,533 | 12 | 237 | 516 | 51 | 1,069 | 50 | 0 | 314 | 127 | 354 | 1 | 5 | 6 | 7 | 1 | 4 | 7 | 12 | 16 | 16 | 18 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Investments |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 152 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 396 | 383 | 0 | 0 | 0 | 0 | 79 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 5 | 0 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Receivables |
| 240 | 245 | 2,563 | 7,953 | 8,034 | 45,591 | 39,829 | 26,395 | 21,798 | 20,846 | 18,478 | 19,137 | 17,364 | 11,522 | 3,254 | 4,282 | 4,156 | 3,071 | 10,668 | 7,293 | 7,138 | 6,192 | 11,192 | 4,421 | 3,424 | 2,554 | 2,210 | 2,279 | 3,095 | 1,546 | 2,135 | 3,260 | 3,143 | 2,731 | 2,619 | 2,071 | 1,439 | 677 | 811 | 0 | 112,230 | 29 | 37 | 37 | 39 | 23 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Current Assets |
| 952 | 1,112 | 642 | 734 | 1,047 | 1,057 | 4,704 | 2,351 | 4,262 | 5,699 | 4,770 | 2,154 | 1,880 | 1,150 | 1,715 | 1,790 | 2,493 | 2,664 | 1,880 | 1,567 | 1,622 | 1,387 | 1,305 | 1,833 | 792 | 909 | 841 | 1,668 | 1,453 | 1,317 | 779 | 1,371 | 1,117 | 973 | 1,118 | 399 | 628 | 682 | 105 | 96 | 112 | 29 | 57 | 37 | 39 | 23 | 10 | 27 | 47 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Long-term Assets |
| 28,229 | 28,964 | 10,476 | 36,523 | 45,472 | 43,817 | 44,610 | 38,834 | 37,341 | 34,528 | 34,083 | 28,863 | 27,710 | 27,397 | 27,607 | 15,769 | 14,884 | 14,279 | 66,516 | 58,826 | 57,463 | 60,838 | 45,150 | 44,642 | 33,295 | 33,842 | 32,577 | 31,748 | 30,157 | 28,844 | 29,282 | 31,263 | 31,599 | 31,145 | 30,542 | 32,551 | 32,073 | 25 | 19 | 21 | 20 | 17 | 17 | 16 | 15 | 15 | 10 | 9 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 15 | 15 | 15 | 15 | 0 | 15 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property Plant Equipment |
| 17,706 | 18,208 | 1,826 | 1,934 | 1,743 | 24,712 | 25,138 | 17,566 | 15,145 | 11,990 | 11,286 | 6,828 | 5,353 | 4,810 | 4,547 | 3,514 | 2,900 | 3,088 | 34,039 | 27,337 | 24,283 | 27,137 | 11,901 | 11,056 | 7,517 | 5,617 | 5,104 | 5,025 | 4,807 | 4,584 | 4,573 | 4,915 | 4,787 | 4,564 | 4,296 | 4,320 | 4,008 | 18 | 13 | 16 | 15 | 12 | 14 | 13 | 13 | 13 | 8 | 9 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill |
| 1,211 | 1,211 | 1,211 | 3,703 | 3,703 | 8,069 | 8,187 | 7,764 | 8,174 | 8,329 | 8,403 | 8,414 | 8,599 | 8,602 | 8,745 | 4,763 | 4,658 | 4,592 | 14,941 | 14,489 | 15,066 | 15,002 | 15,165 | 15,632 | 10,549 | 11,013 | 10,684 | 10,683 | 10,048 | 9,557 | 9,584 | 10,049 | 10,059 | 9,812 | 9,535 | 10,103 | 9,887 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long Term Investments |
| 8 | 8 | 8 | 22,509 | 31,484 | 136 | 136 | 1,739 | 1,750 | 0 | 1,574 | 397 | 160 | 0 | 160 | 175 | 3,211 | 0 | 3,161 | 2,623 | 0 | 0 | 85 | 91 | 1,136 | 1,712 | 1,321 | 475 | 252 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible Assets |
| 8,724 | 8,950 | 7,375 | 7,528 | 7,681 | 9,430 | 9,694 | 10,720 | 11,207 | 11,539 | 11,821 | 12,064 | 12,435 | 12,675 | 13,023 | 3,041 | 3,044 | 3,074 | 14,206 | 14,256 | 15,396 | 15,823 | 16,700 | 17,576 | 14,011 | 15,076 | 15,051 | 15,480 | 14,969 | 14,626 | 15,050 | 16,220 | 16,683 | 16,707 | 16,653 | 18,087 | 18,138 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 15 | 15 | 15 | 15 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Assets |
| 0 | 0 | 0 | 0 | 861 | 0 | 0 | 1,045 | 1,065 | 0 | 1,096 | 1,160 | 1,163 | 0 | 2,766 | 1,398 | 4,282 | 0 | 3,525 | 3,330 | 2,718 | 843 | 1,299 | 287 | 82 | 424 | 27,473 | 26,723 | 25,350 | 24,260 | 24,709 | 26,348 | 26,812 | 26,581 | 26,246 | 28,231 | 28,065 | 6 | 6 | 5 | 5 | 4 | 0 | 3 | 3 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Total Liabilities |
| 46,369 | 58,469 | 35,535 | 32,902 | 30,802 | 33,959 | 31,654 | 40,440 | 30,956 | 23,681 | 21,210 | 21,943 | 24,058 | 27,358 | 24,956 | 23,944 | 30,807 | 37,546 | 86,417 | 68,502 | 67,801 | 63,369 | 46,798 | 39,332 | 21,232 | 22,933 | 25,749 | 26,171 | 26,369 | 30,557 | 22,909 | 22,720 | 21,219 | 19,518 | 45,188 | 41,510 | 39,632 | 4,850 | 5,228 | 5,758 | 1,741 | 1,993 | 1,906 | 2,149 | 2,101 | 358 | 329 | 193 | 243 | 160 | 85 | 26 | 24 | 23 | 12 | 7 | 5 | 4 | 6 | 6 | 3 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Total Current Liabilities |
| 31,700 | 29,031 | 16,407 | 14,302 | 12,711 | 13,938 | 15,910 | 34,168 | 16,245 | 15,253 | 15,365 | 13,566 | 18,156 | 18,930 | 16,285 | 12,355 | 19,758 | 25,910 | 31,579 | 24,363 | 23,064 | 21,752 | 17,145 | 14,953 | 12,972 | 16,164 | 16,914 | 17,571 | 16,147 | 18,123 | 14,576 | 14,924 | 14,408 | 12,412 | 16,476 | 10,393 | 8,218 | 4,438 | 4,663 | 4,318 | 1,179 | 1,249 | 740 | 986 | 696 | 356 | 327 | 192 | 243 | 160 | 85 | 26 | 24 | 23 | 12 | 7 | 5 | 4 | 6 | 6 | 3 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt |
| 3,644 | 3,511 | 3,554 | 3,207 | 2,616 | 3,051 | 5,106 | 22,991 | 5,984 | 3,826 | 6,384 | 4,876 | 7,217 | 4,819 | 4,623 | 708 | 650 | 710 | 3,192 | 2,890 | 2,871 | 2,536 | 1,025 | 1,019 | 933 | 1,958 | 3,158 | 3,165 | 2,605 | 5,467 | 5,491 | 5,501 | 5,307 | 5,011 | 7,739 | 4,805 | 3,676 | 2,523 | 2,451 | 2,629 | 0 | 371 | 258 | 264 | 237 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short Long Term Debt |
| 3,117 | 2,970 | 2,970 | 2,970 | 2,344 | 2,314 | 2,314 | 22,488 | 5,568 | 0 | 3,357 | 4,382 | 6,719 | 0 | 4,327 | 4,119 | 393 | 0 | 383 | 1,179 | 1,022 | 1,013 | 746 | 1,019 | 933 | 1,958 | 3,158 | 8,006 | 7,661 | 5,469 | 4,822 | 0 | 0 | 0 | 2,854 | 0 | 0 | 0 | 2,451 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts payable |
| 13,413 | 16,404 | 6,584 | 4,983 | 3,826 | 4,387 | 4,429 | 4,538 | 5,203 | 6,933 | 5,238 | 3,056 | 5,212 | 10,294 | 8,649 | 3,587 | 1,625 | 1,397 | 11,305 | 7,693 | 6,786 | 5,522 | 3,804 | 2,962 | 2,388 | 3,838 | 3,914 | 3,689 | 3,541 | 4,056 | 4,554 | 4,288 | 4,209 | 2,865 | 3,475 | 2,788 | 2,392 | 524 | 1,084 | 237 | 191 | 171 | 151 | 139 | 59 | 135 | 136 | 57 | 43 | 17 | 45 | 7 | 7 | 22 | 7 | 7 | 4 | 3 | 2 | 0 | 3 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Current Liabilities |
| 5,190 | 6,421 | 4,089 | 4,736 | 4,788 | 4,804 | 4,727 | 5,177 | 3,844 | 3,208 | 2,446 | 4,467 | 4,531 | 2,632 | 2,262 | 7,536 | 16,945 | 22,985 | 5,706 | 5,337 | 4,848 | 4,651 | 5,275 | 3,490 | 3,640 | 3,795 | 4,512 | 3,795 | 3,636 | 3,674 | 3,015 | 3,189 | 3,139 | 2,874 | 3,739 | 1,688 | 1,497 | 838 | 1,043 | 1,342 | 988 | 708 | 121 | 584 | 400 | 221 | 191 | 136 | 200 | 143 | 41 | 19 | 18 | 1 | 5 | 1 | 1 | 1 | 5 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Long-term Liabilities |
| 14,669 | 29,438 | 19,128 | 18,600 | 18,091 | 20,021 | 15,744 | 6,272 | 14,711 | 8,428 | 5,845 | 8,377 | 5,902 | 8,428 | 8,671 | 11,589 | 11,049 | 11,636 | 54,838 | 44,139 | 44,737 | 41,617 | 29,653 | 24,379 | 8,260 | 6,769 | 8,835 | 8,600 | 10,222 | 12,434 | 8,333 | 7,796 | 6,811 | 7,106 | 28,712 | 31,117 | 31,413 | 412 | 565 | 1,440 | 562 | 743 | 1,165 | 1,162 | 1,405 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long term Debt Total |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10,503 | 10,262 | 0 | 10,853 | 14,061 | 10,343 | 3,393 | 2,700 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Liabilities |
| 0 | 0 | 0 | 0 | 60 | 0 | 578 | 564 | 387 | 0 | 387 | 388 | 402 | 0 | 394 | 387 | 348 | 0 | 393 | 2,298 | 2,405 | 2,175 | 2,800 | 3,933 | 236 | 318 | 6 | 1,151 | 3,139 | 5,068 | 2,121 | 2,224 | 1,735 | 1,455 | 1,387 | 10 | 31 | 412 | 565 | 1,440 | 561 | 743 | 0 | 1,162 | 1,405 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred Long Term Liability |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 20 | 0 | 37 | 1,926 | 0 | 0 | 0 | 0 | 0 | 312 | 690 | 2,608 | 2,027 | 2,373 | 1,862 | 0 | 0 | 0 | 3,327 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> Total Stockholder Equity |
| -15,498 | -27,717 | -20,983 | 12,397 | 23,965 | 27,667 | 27,561 | 30,212 | 31,753 | 34,702 | 38,488 | 43,116 | 51,363 | 54,549 | 52,579 | 86,660 | 88,234 | 89,514 | 5,477 | 10,466 | 16,115 | 20,762 | 28,350 | 29,625 | 25,801 | 19,478 | 14,123 | 11,251 | 9,898 | 5,715 | 10,578 | 13,835 | 15,527 | 16,682 | -6,440 | -5,960 | -5,048 | -3,623 | -2,979 | -4,098 | -1,586 | -1,699 | -1,306 | -2,034 | -968 | -260 | -281 | 156 | -62 | 194 | -83 | -21 | -18 | -16 | -10 | 13 | 18 | 23 | 26 | 0 | 31 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock |
| 5 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 5,998 | 1 | 12 | 12 | 12 | 12 | 11 | 11 | 11 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 8 | 8 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Retained Earnings Total Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -36,707 | -34,280 | 0 | -13,874 | -89,429 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income |
| 302 | 281 | 65 | 71 | 62 | -311 | -270 | -826 | -270 | 56 | 207 | 290 | 519 | 471 | 748 | 292 | 10 | -237 | 213 | -751 | 373 | 185 | 425 | 660 | 1,076 | 2,000 | 1,425 | 1,214 | -216 | -1,300 | -1,205 | -239 | -202 | -782 | -1,286 | -134 | -578 | -120 | -18 | 0 | 0 | 0 | 0 | -5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital Surplus |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 123,073 | 122,502 | 0 | 103,623 | 94,691 | 94,415 | 94,049 | 90,335 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Stockholders Equity |
| 179,486 | 158,384 | 155,571 | 154,553 | 153,477 | 153,425 | 149,089 | 148,199 | 147,828 | 145,024 | 144,793 | 144,179 | 142,038 | 142,189 | 140,147 | 123,073 | 122,502 | 103,386 | 101,518 | 94,688 | 94,788 | 94,234 | 93,186 | 80,549 | 76,907 | 61,211 | 55,759 | 50,732 | 48,682 | 43,762 | 41,400 | 39,889 | 39,200 | 37,019 | 13,605 | 14,156 | 13,120 | 13,281 | 13,143 | 12,569 | 11,588 | 9,680 | 7,648 | 8,640 | 7,049 | 6,201 | 4,850 | 3,893 | 1,800 | 1,181 | 47 | 47 | 53 | 53 | 53 | 55 | 53 | 55 | 53 | 0 | 53 | 0 | 0 |
5.3. Balance Sheets
Currency in USD. All numbers in thousands.